AYTU BIOPHARMA, INC Proceeds from (Repurchase of) Equity
AYTU BIOPHARMA, INC (AYTU) reported Proceeds from (Repurchase of) Equity of $12.90 million for the 12-month period ending 2018-06-30, per its 10-K filed 2018-09-06.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepurchaseOfEquity · last filed 2018-09-06
- AYTU BIOPHARMA, INC proceeds from (repurchase of) equity for the quarter ending 2018-06-30 was $0.00.
- AYTU BIOPHARMA, INC proceeds from (repurchase of) equity for fiscal 2018 was $12.90M.
| Period end | Proceeds from (Repurchase of) Equity 3 month | Proceeds from (Repurchase of) Equity 9 month | Proceeds from (Repurchase of) Equity 12 month |
|---|---|---|---|
| 2018-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-06 | $12.90M 10-K · filed 2018-09-06 | |
| 2018-03-31 | $12.90M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |